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Abstract 26 
Lisdexamfetamine is a novel prodrug of D-amphetamine that is used for the treatment of 27 
attention-deficit/hyperactivity disorder (ADHD). D-amphetamine releases dopamine and 28 
norepinephrine and stimulates the hypothalamic-pituitary-adrenal (HPA) axis, which may 29 
contribute to its reinforcing effects and risk of abuse. However, there is currently no data 30 
available on the effects of lisdexamfetamine on circulating steroids. The goal of the present 31 
study was to assess the effects of lisdexamfetamine on circulating steroids compared with D-32 
amphetamine and placebo. Equimolar doses of D-amphetamine (40 mg) and 33 
lisdexamfetamine (100 mg) and placebo were administered in 24 healthy subjects in a 34 
randomized, double-blind, placebo-controlled, cross-over study. Plasma concentrations of 35 
steroids and D-amphetamine were determined up to 24 h. Plasma D-amphetamine 36 
concentrations began to increase and reached peak levels later after lisdexamfetamine 37 
administration compared with D-amphetamine administration, but the maximal concentrations 38 
and total exposure (area under the curve [AUC]) were similar. Lisdexamfetamine and D-39 
amphetamine significantly increased plasma concentrations of adrenocorticotropic hormone, 40 
glucocorticoids (cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, and 11-41 
deoxycortisol), androgens (dehydroepiandrosterone, dehydroepiandrosterone sulfate, and 42 
∆4-androstene-3,17-dione [androstenedione]), and progesterone (only in men) compared with 43 
placebo. Steroid concentration-time curves were shifted to later time points because of a non-44 
significantly later onset after lisdexamfetamine administration compared with D-amphetamine, 45 
but maximal plasma steroid concentrations and AUCs did not differ between the active 46 
treatments. None of the active treatments altered plasma concentrations of the 47 
mineralocorticoids aldosterone and 11-deoxycorticosterone or the androgen testosterone 48 
compared with placebo. The effects of the amphetamines on glucocorticoid production were 49 
similar to those that were previously reported for methylphenidate (60 mg) but weaker than 50 
those for the serotonin releaser 3,4-methylenedioxymethamphetamine (MDMA; 125 mg) or 51 
direct serotonin receptor agonist lysergic acid diethylamide (LSD; 0.2 mg). Lisdexamfetamine 52 
produced comparable HPA axis activation and had similar pharmacokinetics compared with 53 
D-amphetamine, with the exception of a later time of onset. Thus, serotonin (MDMA, LSD) 54 
may more effectively stimulate the HPA axis than dopamine and norepinephrine (D-55 
amphetamine). 56 
 57 
58 
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Introduction 59 
 Lisdexamfetamine is a prodrug of D-amphetamine [1, 2], and both are used for the 60 
treatment of attention-deficit/hyperactivity disorder (ADHD), similar to methylphenidate. In 61 
addition to their use as medications, amphetamines and methylphenidate are also misused 62 
as recreational drugs or neuroenhancers to induce euphoria or stay awake [3-5]. After oral 63 
administration, the conversion of lisdexamfetamine to D-amphetamine is thought to occur 64 
gradually in the circulation [6], resulting in a prolonged pharmacokinetic profile with a low peak 65 
but sustained plasma amphetamine concentrations [7]. Such a prolonged pharmacokinetic 66 
profile is considered to be associated with slower effects on dopamine (DA) release, lower 67 
euphoric effects, and a possibly lower risk of misuse [7-9]. Indeed, in rats, a lower peak plasma 68 
concentration (Cmax) of amphetamine was observed after lisdexamfetamine administration, 69 
together with a gradual and sustained increase in dopamine efflux and much less locomotor 70 
activity compared with D-amphetamine [10]. In humans, 100 mg lisdexamfetamine produced 71 
lower subjective “drug liking” than an equivalent dose of 40 mg D-amphetamine in one study, 72 
although other subjective effects including euphoria and stimulation did not differ between the 73 
two drugs [7]. Moreover, in a recent study of the pharmacokinetics and pharmacodynamics of 74 
lisdexamfetamine and D-amphetamine, we found no difference between the two drugs in the 75 
maximal plasma concentrations of amphetamine or any of their subjective effects [11].  76 
The goal of the present study was to investigate the effects of lisdexamfetamine and D-77 
amphetamine compared with placebo and with each other on circulating steroids. 78 
Amphetamines and methylphenidate enhance subjective mood, concentration, and 79 
wakefulness but also act as acute pharmacological stressors that stimulate the hypothalamic-80 
pituitary-adrenal (HPA) axis to elevate concentrations of circulating stress hormones, including 81 
adrenocorticotropic hormone (ACTH), cortisol, epinephrine, and norepinephrine (NE) [12-16]. 82 
However, the effects of lisdexamfetamine on the HPA axis are unknown. In the US in 2010, 83 
lisdexamfetamine was the third-most prescribed drug for ADHD in pediatrics patients [17]. In 84 
the US, there was also an increase in lisdexamfetamine misuse cases reported to poison 85 
centers between 2007 and 2012, resulting in more cases associated with lisdexamfetamine 86 
than extended-release D-amphetamine [18]. Because, disturbances of HPA axis function, e.g. 87 
the glucocorticoid circadian rhythm, can lead to learning, memory and behavioral deficits, 88 
mood disorders such as depression, impaired immune system, and development of metabolic 89 
syndrome [19-23], information on the effects of lisdexamfetamine on HPA axis function is of 90 
interest. Also unknown is whether lisdexamfetamine produces less HPA axis activation than 91 
D-amphetamine based on its reportedly prolonged kinetic characteristics [7-9]. Animal studies 92 
indicate that HPA axis stimulation may be associated with a greater risk of drug abuse. 93 
Specifically, rats that exhibit greater HPA axis reactivity or were administered corticosterone 94 
more likely self-administered D-amphetamine [24]. These observations suggest that 95 
lisdexamfetamine may have a lower risk of oral abuse compared with D-amphetamine 96 
because of a slowed increase in plasma D-amphetamine concentrations and consequently a 97 
lower HPA response. Therefore, we directly compared plasma ACTH and steroid 98 
concentrations after administration of equivalent and relatively high doses of D-amphetamine 99 
and lisdexamfetamine. The pharmacokinetic, subjective, and cardiovascular effects have 100 
been reported in detail elsewhere [11] and selected effects are also shown here. The primary 101 
hypothesis of the present study was that lisdexamfetamine would produce a lower Cmax and 102 
longer time to Cmax (Tmax) for both D-amphetamine and plasma steroids compared with 103 
immediate-release D-amphetamine. Equimolar doses of lisdexamfetamine and D-104 
amphetamine were expected to result in equivalent areas under the plasma concentration-105 
time curve (AUCs) for D-amphetamine and steroids, confirming the use of equivalent doses.  106 
The present study used relatively high doses of lisdexamfetamine and D-amphetamine. 107 
D-Amphetamine at low oral doses of 10-20 mg has been repeatedly shown to increase plasma 108 
and saliva cortisol concentrations [16, 25-31], with no effect on plasma cortisol levels [32]. 109 
Few studies used higher doses of D-amphetamine that would possibly better reflect stimulant 110 
misuse. One study reported an increase in plasma cortisol levels compared with baseline after 111 
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34 mg D-amphetamine [33]. However, this previous study did not include a placebo control 112 
condition. Therefore, the present study investigated the effects of relatively high doses of D-113 
amphetamine (40 mg) and lisdexamfetamine (100 mg) and placebo on plasma concentrations 114 
of ACTH and primarily cortisol and other circulating steroids that have not been previously 115 
measured.  116 
Both amphetamine and methylphenidate enhance DA and NE neurotransmission [34]. 117 
D-amphetamine releases DA and NE from presynaptic terminals and inhibits their reuptake 118 
[35]. Methylphenidate only inhibits their reuptake without inducing transporter-mediated 119 
release [36]. Although methylphenidate stimulates DA and NE systems similarly to D-120 
amphetamine, methylphenidate produced only moderate stimulating effects on the HPA axis 121 
[13, 15]. Specifically, single low oral doses of 10-20 mg methylphenidate had no significant 122 
effect on plasma cortisol concentrations compared with placebo [29]. A single intermediate 123 
oral dose of 40 mg methylphenidate only moderately increased plasma cortisol levels [14]. A 124 
high dose of 60 mg methylphenidate non-significantly increased plasma levels of cortisol, 125 
cortisone, corticosterone, and 11-dehydrocorticosterone compared with placebo [13, 15]. 126 
Interestingly, the relatively high dose of 60 mg methylphenidate produced at least similar 127 
subjective “drug liking” to 30 mg D-amphetamine [15, 37], indicating that methylphenidate may 128 
induce lower HPA axis stimulation than D-amphetamine at doses producing similar subjective 129 
drug liking. This view is supported by a study that directly compared plasma cortisol 130 
concentrations after low 10-20 mg doses of both D-amphetamine and methylphenidate [29], 131 
but higher doses of both drugs have not been directly or indirectly compared. Therefore, the 132 
present study also indirectly compared the effects of a high dose of 40 mg D-amphetamine 133 
with a high dose of 60 mg methylphenidate that was previously tested in the same laboratory 134 
in a similar healthy population using the same clinical and analytical methods [13]. Based on 135 
previous data [13, 15, 29], the hypothesis was that D-amphetamine would produce greater 136 
HPA axis activation than methylphenidate. 137 
A final goal of the present study was to explore the role of different monoamine 138 
neurotransmitters in regulating HPA activity. D-amphetamine releases both DA and NE and 139 
may release cortisol mainly via NE [38]. In contrast, the amphetamine derivative 3,4-140 
methylenedioxymethamphetamine (MDMA) mainly releases serotonin (5-hydroxytryptamine 141 
[5-HT]) and NE [35, 39, 40]. Therefore, MDMA and D-amphetamine may be useful as 142 
pharmacological modulators to study the impact of 5-HT vs. DA release on HPA axis 143 
stimulation. Accordingly, we indirectly compared the effects of D-amphetamine on plasma 144 
steroid concentrations with those after 125 mg oral MDMA that was previously tested in the 145 
same laboratory using the same clinical and analytical methods [13]. To further study the role 146 
of 5-HT vs. DA and NE release in psychoactive substance-induced HPA axis stimulation in 147 
humans, we also compared the effects of D-amphetamine with similar historical data [41] on 148 
the direct 5-HT receptor agonist lysergic acid diethylamide (LSD) [42]. We hypothesized that 149 
MDMA and LSD would produce greater increases in cortisol in humans than D-amphetamine. 150 
This would indicate a more prominent role for 5-HT compared with DA and NE in stimulating 151 
the main human glucocorticoid cortisol by psychoactive substances and further establish 152 
cortisol as a marker of acute serotonergic activity [41, 43]. 153 
 154 
Materials and Methods 155 
Study design 156 
 The protocol of the clinical trial (Protocol S1) and the CONSORT checklist (Checklist 157 
S1) are available as supporting information. The CONSORT flowchart is depicted in Figure 1. 158 
The study used a double-blind (subjects and study personnel), placebo-controlled, cross-over 159 
design with three experimental test days (D-amphetamine, lisdexamfetamine, and placebo). 160 
The treatment sequence was randomly selected from four blocks of all possible six sequences 161 
and all treatments were counterbalanced. The washout periods between sessions were at 162 
least 7 days. The study was conducted in accordance with the Declaration of Helsinki and 163 
International Conference on Harmonization Guidelines in Good Clinical Practice and approved 164 
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by the Ethics Committee northwest/central Switzerland (EKNZ) and Swiss Agency for 165 
Therapeutic Products (Swissmedic). The study was registered at ClinicalTrials.gov 166 
(NCT02668926). All of the subjects provided written informed consent prior to participating in 167 
the study. 168 
 169 
Figure 1. CONSORT flowchart. The treatment sequence was randomly selected from four 170 
blocks of all possible six sequences and all treatments were counterbalanced. 171 
 172 
Participants 173 
 Twenty-four healthy subjects (12 men and 12 women; mean age ± SD: 25.3 ± 3.0 174 
years; range: 21-34 years) were included. The allocation to treatment order was conducted by 175 
drawing from blocks of six different balanced drug treatment sequences by a pharmacist of 176 
the University Hospital Basel not involved in the study. Each code was stored in a sealed 177 
envelope until the termination of the study. The sample-size estimation showed that 15 178 
subjects would be needed to detect a meaningful difference of 20% in Cmax levels between D-179 
amphetamine and lisdexamfetamine with more than 80% power using a within-subjects study 180 
design. The inclusion criteria were age between 18 and 45 years, body mass index between 181 
18 and 27 kg/m2, and birth control for women. The exclusion criteria were chronic or acute 182 
medical conditions, including clinically relevant abnormalities on physical exam, laboratory 183 
values, or electrocardiography, personal or family (first-degree relative) history of psychotic or 184 
major affective disorder, lifetime prevalence of illicit drug use > 5 times (except for 185 
tetrahydrocannabinol), illicit drug use within the last 2 months, pregnancy, regular use of 186 
medications, smoking (> 10 cigarettes/day), and alcohol consumption (> 10/week). The 187 
subjects were asked to abstain from excessive alcohol consumption between test sessions 188 
and not drink caffeine-containing drinks after midnight before the study day. Urine drug tests 189 
were performed at study inclusion and before each test session using TRIAGE 8 (Biosite, San 190 
Diego, CA, USA). 191 
 192 
Drugs 193 
 Gelatin capsules that contained either lisdexamfetamine dimesylate (100 mg salt; 194 
Opopharma, Rümlang, Switzerland) or D-amphetamine sulfate (40.3 mg salt; Hänseler, 195 
Herisau, Switzerland), both corresponding to a dose of 29.6 mg D-amphetamine, and placebo 196 
capsules (mannitol) were prepared, and randomized by the pharmacy of the University 197 
Hospital Basel according to Good Manufacturing Practice. The recommended doses of 198 
lisdexamfetamine for the treatment of ADHD are 30-70 mg/day, with an initial dose of 30 mg. 199 
The selected dose of 100 mg lisdexamfetamine was relatively high and above the upper 200 
recommended daily dose of 70 mg to induce greater subjective drug liking and mimic misuse, 201 
and to produce similar plasma concentrations after a single dose to those reached during 202 
repeated administration of 70 mg when steady state is reached.  203 
 204 
Study procedures 205 
 Before the test session, a urine sample was taken to verify abstinence from drugs of 206 
abuse, and a pregnancy test was performed in women. The test session began at 8:00 AM by 207 
placing an indwelling intravenous catheter in an antecubital vein for blood sampling. At 9:00 208 
AM, a single dose of lisdexamfetamine, D-amphetamine, or placebo was administered orally. 209 
During the test session, the subjects did not engage in any physical activity, were resting in 210 
hospital beds in a calm standard hospital room, and were served a standardized lunch and 211 
dinner at 11:30 AM and 6:30 PM, respectively. For the analysis of hormone and D-212 
amphetamine concentrations in plasma, blood samples were collected in lithium heparin tubes 213 
1 h before and 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. 214 
The blood samples were immediately centrifuged, and plasma was stored at -20°C. For the 215 
determination of ACTH concentrations, blood samples were drawn into 216 
ethylenediaminetetraacetic acid-containing tubes 1 h before and 3.5 h after drug 217 
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administration. The test session ended at 9:00 PM. The subjects returned home and returned 218 
the following day at 9:00 AM to draw the final 24 h blood sample. Subjective, autonomic, and 219 
adverse responses were also assessed and have been reported in detail elsewhere [11]. 220 
 221 
Steroid quantification in plasma 222 
 The following plasma steroid hormones with the corresponding lower limit of 223 
quantification (LLOQ; values in brackets) were determined using a previously published ultra-224 
high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) 225 
method [41] with minor modifications: cortisol [1.95 nM], cortisone [1.95 nM], corticosterone 226 
[0.98 nM], 11-dehydrocorticosterone [0.98 nM], 11-deoxycorticosterone [0.78 nM], 227 
aldosterone [0.2 nM], dehydroepiandrosterone (DHEA) [3.91 nM], DHEA sulfate (DHEAS) 228 
[19.53 nM], ∆4-androstene-3,17-dione (androstenedione) [0.78 nM], testosterone [0.39 nM], 229 
11-deoxycortisol [0.78 nM], progesterone [0.05 nM], androsterone [3.91 nM], and 17α-230 
hydroxyprogesterone [0.78 nM]. The accuracy was between 85% and 115%, and the 231 
coefficient of variation was < 15%, tested at three concentrations for all analytes. The recovery 232 
of control samples was in the range of 80-120%. The details of the applied method and its 233 
validation were reported previously [41]. Briefly, after protein precipitation, plasma samples 234 
that contained deuterium-labeled aldosterone, corticosterone, androstenedione, 235 
androsterone, and testosterone as internal standards were solid-phase extracted. After 236 
evaporation and reconstitution in methanol, the steroids were separated and quantified by 237 
UHPLC-MS/MS using an Agilent 1290 UPLC device coupled to an Agilent 6490 triple 238 
quadrupole mass spectrometer equipped with a jet-stream electrospray ionization interface. 239 
Analyte separation was achieved using a reverse-phase column (Waters Acquity UPLC BEH 240 
C18, 1.7 µm, 2.1 × 150 mm). Mass Hunter software (Agilent Technologies) was used for data 241 
acquisition and analysis. 242 
 243 
Quantification of adrenocorticotropic hormone in human 244 
plasma samples 245 
 ACTH was determined by a chemiluminescent immunometric assay (Immulite 2000 246 
ACTH; Siemens, Erlangen, Germany). 247 
 248 
Quantification of D-amphetamine concentrations in plasma 249 
Plasma D-amphetamine concentrations were measured using an UHPLC-MS/MS 250 
method. Materials, procedures, and method validation are described in detail in the 251 
Supplementary Material. The method had a lower limit of detection (LOD) of 0.26 ng/ml and 252 
LLOQ of 0.78 ng/ml for D-amphetamine and was validated over the range of 0.78 to 200 ng/ml 253 
for D-amphetamine. Plasma D-amphetamine concentrations were primarily measured to 254 
confirm the use of bioequivalent lisdexamfetamine and D-amphetamine doses with regard to 255 
total D-amphetamine exposure and to assess D-amphetamine-steroid response relationships. 256 
The comprehensive pharmacokinetic data from this study have been reported elsewhere [11].  257 
 258 
Subjective effects 259 
Visual Analog Scales (VASs) were repeatedly used to assess subjective drug effects 260 
over time. The VASs "drug liking", “good drug effects”, “drug high”, and “stimulated” were 261 
presented as 100 mm horizontal lines (0 to +100), marked from "not at all" on the left to 262 
"extremely" on the right. The VASs were administered 1 h before and 0, 0.5, 1, 1.5, 2, 2.5, 3, 263 
3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, and 24 h after drug administration. 264 
 265 
Statistical analyses 266 
 Cmax, Emax, and Tmax were derived directly from the observed data. The time to reach 267 
10% of Cmax (Tonset) and areas under the concentration-time curve from time 0 to 12 h (AUC12) 268 
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were calculated using the linear trapezoidal method in Phoenix WinNonlin 6.4 software 269 
(Pharsight, St. Louis, MO). The statistical analyses were performed using Statistica 12 270 
software (StatSoft, Tulsa, OK, USA) and the computing environment R (R Development Core 271 
Team, 2017, Vienna, Austria). Kinetic parameters and subjective effect ratings (Emax) were 272 
compared using repeated-measures analysis of variance (ANOVA), with drug (D-273 
amphetamine, lisdexamfetamine, and placebo) as the within-subjects factor, followed by the 274 
Tukey post hoc test. Means of the effect sizes are displayed with confidence intervals of 95%. 275 
P-Values of the multiple ANOVAs were Bonferroni-adjusted for the 14 different hormones 276 
tested. Additionally, sex differences were assessed by adding sex as a between-subjects 277 
factor in addition to drug in complementary ANOVAs. Furthermore, supplementary ANOVAs 278 
with order as additional factor were performed to exclude treatment order effects (absence of 279 
drug × order interactions). Plasma amphetamine concentration-effect relationships were 280 
studied by plotting endocrine responses as a difference from time-matched placebo against 281 
the plasma amphetamine concentration for each time point. Selected peak endocrine effects 282 
of D-amphetamine and lisdexamfetamine were calculated as differences from placebo and 283 
then compared with the effects of 60 mg methylphenidate [13], 125 mg MDMA [13], and 200 284 
µg LSD [41] (also as placebo-corrected responses) using ANOVA, with drug as the between-285 
subjects (between-studies) factor, followed by the Tukey post hoc test. The data for 286 
methylphenidate, MDMA, and LSD were obtained from previous identical studies in healthy 287 
subjects in the same laboratory. The use of placebo-corrected values accounted for between-288 
subject differences in baseline steroid levels and circadian within-subject changes. 289 
 290 
Results 291 
 Blood could not be drawn from one subject in the D-amphetamine and from one subject 292 
in the placebo condition. Therefore, complete datasets were available for D-amphetamine, 293 
placebo, and lisdexamfetamine for 23, 23, and 24 subjects, respectively. 294 
 295 
Plasma amphetamine levels after administration of D-296 
amphetamine and lisdexamfetamine and subjective effects 297 
The plasma amphetamine concentration-time curves were identical after 298 
administration of D-amphetamine and lisdexamfetamine, with the exception of a significantly 299 
longer Tonset and Tmax after lisdexamfetamine administration compared with D-amphetamine 300 
administration (Fig. 2, Table 1). The Cmax and AUC12 values were similar (Table 1). Subjective 301 
drug effects over time are shown in Fig. 2. The effects in "drug liking", “good drug effect”, “drug 302 
high”, and “stimulated” between Lisdexamfetamine and D-amphetamine in compared with 303 
placebo (Table 1, Fig. 2) did not increase differently. The subjective drug effect-time curves 304 
were shifted to the right (Fig. 2) as evidenced by significantly longer time to onset and time to 305 
maximal effect values after lisdexamfetamine administration compared with D-amphetamine 306 
administration (Table 1), reflecting the pharmacokinetics of the two drugs. However, no 307 
differences in Emax values were found between lisdexamfetamine and D-amphetamine (Table 308 
1). The pharmacokinetics and additional pharmacodynamic effects are reported in more detail 309 
elsewhere [11]. 310 
 311 
Figure 2. Plasma concentration of amphetamine and subjective drug effects following 312 
administration of D-amphetamine, lisdexamfetamine and placebo. D-Amphetamine, 313 
lisdexamfetamine, or placebo was administered at t = 0 h. Values for amphetamine (A) are 314 
mean ± SEM in 23, 24, and 23 subjects after administration of D-amphetamine, 315 
lisdexamfetamine and placebo. Plasma concentration-time curves of amphetamine were 316 
similar after administration of lisdexamfetamine compared with D-amphetamine with the 317 
exception of a significantly later onset and therefore longer time to reach maximal 318 
concentrations. However, maximal concentrations of amphetamine and areas under the 319 
concentration-time curves were similar after the two treatments. The effect onset and maximal 320 
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response of the subjective effects ("drug liking" (B), “good drug effect” (C), “drug high” (D), 321 
and “stimulated” (E)) were significantly delayed after lisdexamfetamine administration 322 
compared with D-amphetamine administration but the maximal effects and curve shapes were 323 
similar, reflecting the pharmacokinetics of the two substances. The subjective response data 324 
are expressed as the mean ± SEM in 24 subjects. 325 
 326 
  327 
Strajhar et al. 
 9
Table 1. Kinetic parameters of plasma steroids and amphetamine after D-amphetamine, lisdexamfetamine, or placebo. 328 
      D-Amphetamine Lisdexamfetamine Placebo 
Main 
effect of 
drug 
(a,b,cF2,42) 
p value 
(non-
corrected) 
p value 
Bonferroni 
adjusted 
Lisdexamfetamine -                
D-Amphetamine                
Mean (CI. low, CI. 
High) 
p value 
Placebo -                                 
D-Amphetamine               
Mean (CI. low, CI. 
High) 
p value 
Placebo - 
Lisdexamfetamine           
Mean (CI. low, CI. 
High) 
p value 
Amphetamine Tonset 0.8 ± 0.1 1.4 ± 0.1  33.86 <0.001  0.57 (0.37, 0.78) 
 
  
 
  
   
Tmax 3.2 ± 0.2 4.4 ± 0.2  16.47 <0.001  1.0 (0.51, 1.58) 
 
 
 
 
   
Cmax 134 ± 7 128 ± 5  0.88 NS  -3.0 (-13, 7.2) 
 
 
 
 
   
AUC12 1014 ± 47 983 ± 42  0.66 NS  -7.4 (-56, 42) 
 
 
 
 
 
Subjective effects         
 
 
 
 
 
 Drug liking Tonset 0.9 ± 0.1 1.6 ± 0.2  11.1 0.0035        
  Tmax 2.7 ± 0.4 4.5 ± 0.5  6.66 0.04        
  Emax 51.2 ± 5.8 48.0 ± 6.9 3.7 ± 2.6 38.8 <0.001  -3.2 (-17, 11) NS -48 (-62, -33) <0.001 -44 (-58, -44) <0.001 
  AUC12 251 ± 43 260 ± 52 5.2 ± 4.3 17.8 <0.001  9.0 (-105, 122) NS -246 (-359, -132) <0.001 -255 (-368, -255) <0.001 
 Good drug effect Tonset 0.9 ± 0.1 1.5 ± 0.1  8.3 0.0092        
  Tmax 2.8 ± 0.3 4.4 ± 0.5  7.46 0.013        
  Emax 48.5 ± 5.6 41.8 ± 6.5 4.0 ± 2.5 30.2 <0.001  -4.4 (-18, 9.6) NS -42 (-56, -28) <0.001 -38 (-52, -38) <0.001 
  AUC12 226 ± 42 236 ± 51 5.4 ± 4.4 14.8 <0.001  9.6 (-103, 122) NS -221 (-333, -108) <0.001 -230 (-343, -230) <0.001 
 Drug high Tonset 1.0 ± 0.1 1.9 ± 0.3  8.19 0.01        
  Tmax 2.4 ± 0.2 3.6 ± 0.4  7.04 0.016        
  Emax 35.5 ± 5.6 29.3 ± 6.2 3.3 ± 2.6 16.8 <0.001  -6.2 (-20, 7.7) NS -32 (-46, -18) <0.001 -26 (-40, -26) <0.001 
  AUC12 134 ± 30 125 ± 33 2.5 ± 1.9 10.3 <0.001  -8.8 (-84, 67) NS -131 (-207, -56) <0.001 -123 (-198, -123) <0.001 
 Stimulated Tonset 1.0 ± 0.1 1.8 ± 0.3  6.19 0.022        
  Tmax 2.3 ± 0.2 4.4 ± 1.0  5.88 0.025        
  Emax 43.8 ± 5.7 38.0 ± 6.8 2.4 ± 1.7 26 <0.001  -5.8 (-20, 8.8) NS -41 (-56, -27) <0.001 -36 (-50, -36) <0.001 
  AUC12 178 ± 30 152 ± 35 1.7 ± 1.1 16.1 <0.001  -26 (-105, 52) NS -176 (-255, -98) <0.001 -150 (-228, -150) <0.001 
Glucocorticoids              
 
Cortisol  Tmax 2.72 ± 0.29 3.17 ± 0.41 1.20 ± 0.41 7.54 0.0016 0.022 0.59 (-0.69, 1.9) NS -1.5 (-2.8, -0.19) 0.019 -2.1 (-3.4, -2.1) <0.001 
 
 Cmax 534 ± 28.9 519 ± 24.9 417 ± 35.2 17.5 <0.001 <0.001 -26 (-80, 27) NS -128 (-181, -74) <0.001 -102 (-155, -102) <0.001 
 
 AUC12 4116 ± 286 4207 ± 287 2621 ± 252 62.2 <0.001 <0.001 -56 (-414, 301) NS -1501 (-1858, -1143) <0.001 -1444 (-1801, -1444) <0.001 
 
Cortisone  Tmax 4.39 ± 0.3 4.67 ± 0.3 2.80 ± 0.5 6.86 0.0026 0.037 0.32 (-0.91, 1.5) NS -1.5 (-2.7, -0.27) 0.012 -1.8 (-3.0, -1.8) 0.0015 
 
 Cmax 80.6 ± 4.2 82.8 ± 4.3 58.0 ± 3.0 36.3 <0.001 <0.001 0.50 (-7.1, 8.1) NS -24 (-31, -16) <0.001 -24 (-32, -24) <0.001 
 
 AUC12 707 ± 35.2 739 ± 35.5 503 ± 26.4 47.1 <0.001 <0.001 19 (-41, 78) NS -203 (-262, -144) <0.001 -222 (-281, -222) <0.001 
 
Corticosterone  Tmax 2.59 ± 0.47 3.0 ± 0.38 2.24 ± 0.5 1.15 NS NS 0.59 (-0.75, 1.9) NS -0.25 (-1.6, 1.1) NS -0.84 (-2.2, -0.84) NS 
 
 Cmax 22.6 ± 2.6 20.1 ± 2.0 11.6 ± 1.4 15.8 <0.001 <0.001 -2.3 (-7.4, 2.8) NS -12 (-17, -6.5) <0.001 -9.2 (-14, -9.2) <0.001 
 
 AUC12 85.1 ± 6.2 83.1 ± 6.0 36.6 ± 3.2 62.7 <0.001 <0.001 -3.0 (-14, 8.4) NS -49 (-60, -37) <0.001 -46 (-57, -46) <0.001 
 
11-Dehydro- Tmax 2.96 ± 0.48 2.88 ± 0.38 2.46 ± 0.55 0.4 NS NS 0.07 (-1.3, 1.4) NS -0.41 (-1.8, 0.95) NS -0.48 (-1.8, -0.48) NS 
 
corticosterone  Cmax 8.93 ± 0.86 8.82 ± 0.64 5.43 ± 0.53 23.5 <0.001 <0.001 -0.13 (-1.6, 1.4) NS -3.8 (-5.3, -2.3) <0.001 -3.7 (-5.2, -3.7) <0.001 
 
 AUC12 51.4 ± 4.0 53.7 ± 3.2 28.8 ± 2.2 65.7 <0.001 <0.001 1.6 (-4.1, 7.2) NS -23 (-29, -17) <0.001 -25 (-30, -25) <0.001 
 
Cortisol + Tmax 2.93 ± 0.3 3.65 ± 0.38 1.20 ± 0.41 9.85 <0.001 0.0043 0.61 (-0.66, 1.9) NS -1.7 (-3.0, -0.44) 0.0046 -2.3 (-3.6, -2.3) <0.001 
 
cortisone Cmax 601 ± 31 583 ± 26.5 469 ± 36 20.3 <0.001 <0.001 -29 (-85, 27) NS -144 (-200, -88) <0.001 -115 (-171, -115) <0.001 
 
 AUC12 4824 ± 299 4945 ± 307 3124 ± 266 67.9 <0.001 <0.001 -38 (-429, 354) NS -1704 (-2095, -1312) <0.001 -1666 (-2057, -1666) <0.001 
 
Ratio Tmax 1.83 ± 0.44 3.10 ± 0.61 2.02 ± 0.63 2.79 0.073 NS 1.5 (-0.06, 3.0) 0.064 0.32 (-1.2, 1.9) NS -1.2 (-2.7, -1.2) NS 
 
cortisol/cortisone Cmax 9.42 ± 0.57 9.25 ± 0.49 8.81 ± 0.72 0.66 NS NS -0.31 (-1.7, 1.0) NS -0.66 (-2.0, 0.69) NS -0.35 (-1.7, -0.35) NS 
 
 AUC12 72.3 ± 5.1 69.8 ± 4.0 61.5 ± 5.2 9.93 <0.001 0.0041 -3.9 (-10, 2.4) NS -12 (-18, -5.4) <0.001 -7.8 (-14, -7.8) 0.0097 
 
Corticosterone + Tmax 2.59 ± 0.47 3.0 ± 0.36 2.37 ± 0.54 0.99 NS NS 0.59 (-0.67, 1.8) NS -0.11 (-1.4, 1.1) NS -0.70 (-2.0, -0.70) NS 
 
11-dehydro- Cmax 31.2 ± 3.3 28.5 ± 2.6 16.9 ± 1.9 18 <0.001 <0.001 -2.5 (-8.9, 3.9) NS -15 (-22, -8.8) <0.001 -13 (-19, -13) <0.001 
 
corticosterone AUC12 136 ± 9.5 137.0 ± 8.6 65.3 ± 5.0 74.8 <0.001 <0.001 -1.2 (-17, 15) NS -72 (-87, -56) <0.001 -70 (-86, -70) <0.001 
 
ratio Tmax 2.59 ± 0.44 2.98 ± 0.43 2.39 ± 0.56 0.28 NS NS 0.36 (-1.2, 2.0) NS -0.14 (-1.7, 1.5) NS -0.50 (-2.1, -0.50) NS 
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corticosterone/11- Cmax 3.01 ± 0.24 2.73 ± 0.14 2.24 ± 0.14 7.48 0.0017 0.023 -0.29 (-0.75, 0.18) NS -0.76 (-1.2, -0.29) <0.001 -0.47 (-0.94, -0.47) 0.045 
 
dehydrocorticosterone AUC12 18.7 ± 1.1 17.3 ± 0.93 13.9 ± 1.03 18.1 <0.001 <0.001 -1.5 (-3.5, 0.43) NS -4.9 (-6.8, -2.9) <0.001 -3.4 (-5.3, -3.4) <0.001 
 
11-Deoxycortisol  Tmax 3.02 ± 0.29 3.83 ± 0.32 4.22 ± 0.67 1.99 NS NS 0.77 (-0.76, 2.3) NS 1.3 (-0.23, 2.8) NS 0.52 (-1.0, 0.52) NS 
 
 Cmax 2.70 ± 0.17 2.68 ± 0.17 1.60 ± 0.14 35.3 <0.001 <0.001 -0.02 (-0.39, 0.34) NS -1.1 (-1.5, -0.78) <0.001 -1.1 (-1.5, -1.1) <0.001 
 
 AUC12 17.7 ± 1.08 18.1 ± 1.2 11.0 ± 1.2 46.3 <0.001 <0.001 0.27 (-1.7, 2.2) NS -6.8 (-8.8, -4.9) <0.001 -7.1 (-9.1, -7.1) <0.001 
Mineralocorticoids     
 
        
 
Aldosterone  Tmax 4.11 ± 0.84 3.88 ± 0.73 3.43 ± 0.67 0.03 NS NS -0.11 (-2.4, 2.2) NS -0.25 (-2.5, 2.0) NS -0.14 (-2.4, -0.14) NS 
 
 Cmax 0.31 ± 0.03 0.34 ± 0.03 0.31 ± 0.03 1.42 NS NS 0.01 (-0.01, 0.03) NS -0.01 (-0.03, 0.01) NS -0.02 (-0.04, -0.02) NS 
 
 AUC12 3.06 ± 0.2 3.19 ± 0.21 3.12 ± 0.24 1.76 NS NS 0.12 (-0.03, 0.28) NS 0.06 (-0.09, 0.22) NS -0.06 (-0.22, -0.06) NS 
 
11-Deoxy- Tmax 3.43 ± 0.44 3.85 ± 0.48 2.98 ± 0.65 0.56 NS NS 0.16 (-1.6, 1.9) NS -0.59 (-2.3, 1.2) NS -0.75 (-2.5, -0.75) NS 
 
corticosterone Cmax 0.53 ± 0.08 0.57 ± 0.07 0.49 ± 0.07 2.29 NS NS 0.04 (-0.03, 0.11) NS -0.02 (-0.09, 0.05) NS -0.06 (-0.13, -0.06) 0.088 
 
 AUC12 5.84 ± 0.88 6.10 ± 0.87 5.45 ± 0.86 1.66 NS NS 0.34 (-0.25, 0.94) NS -0.10 (-0.69, 0.50) NS -0.44 (-1.0, -0.44) NS 
Androgens              
 
DHEA  Tmax 3.50 ± 0.53 4.88 ± 0.53 3.76 ± 0.7 1.58 NS NS 1.2 (-0.74, 3.2) NS -0.11 (-2.1, 1.8) NS -1.3 (-3.3, -1.3) NS 
 
 Cmax 80.9 ± 7.0 78.5 ± 6.0 57.1 ± 5.3 8.77 <0.001 0.0092 -0.95 (-16, 14) NS -24 (-39, -8.7) <0.001 -23 (-38, -23) 0.0013 
 
 AUC12 609 ± 41.1 608 ± 43.0 455 ± 36.9 20.2 <0.001 <0.001 13 (-51, 77) NS -143 (-207, -79) <0.001 -156 (-220, -156) <0.001 
 
DHEAS  Tmax 5.40 ± 0.68 5.80 ± 0.58 4.50 ± 0.64 0.94 NS NS 0.45 (-1.6, 2.5) NS -0.73 (-2.8, 1.3) NS -1.2 (-3.2, -1.2) NS 
 
 Cmax 13764 ± 1397 14452 ± 1307 11896 ± 1280 11.8 <0.001 0.0012 855 (-522, 2232) NS -1932 (-3310, -555) 0.003 -2787 (-4165, -2787) <0.001 
 
 AUC12 129057 ± 15047 136822 ± 12643 113005 ± 13334 7.05 0.0023 0.032 8277 (-7361, 23915) NS -16339 (-31977, -701) 0.038 -24616 (-40254, -24616) <0.001 
 
Androsterone  Tmax 4.93 ± 0.89 5.08 ± 0.79 4.74 ± 0.76 0.14 NS NS -0.61 (-3.3, 2.1) NS -0.30 (-3.0, 2.4) NS 0.32 (-2.4, 0.32) NS 
 
 Cmax 6.93 ± 0.44 6.25 ± 0.46 6.42 ± 0.58 0.12 NS NS -0.20 (-1.2, 0.80) NS -0.04 (-1.0, 0.96) NS 0.16 (-0.83, 0.16) NS 
 
 AUC12 46.6 ± 3.6 44.1 ± 3.5 43.3 ± 4.5 0.21 NS NS 0.82 (-4.3, 6.0) NS -0.61 (-5.8, 4.5) NS -1.4 (-6.6, -1.4) NS 
 
Androstenedione Tmax 3.36 ± 0.52 5.13 ± 0.58 2.23 ± 0.81 5.03 0.018 NS 2.0 (-0.23, 4.1) 0.092 -0.95 (-3.1, 1.2) NS -2.9 (-5.1, -2.9) 0.0053 
 
in women Cmax 3.63 ± 0.40 3.46 ± 0.23 2.59 ± 0.24 11.6 <0.001 0.0082 -0.20 (-0.78, 0.38) NS -1.1 (-1.7, -0.53) <0.001 -0.91 (-1.5, -0.91) <0.001 
 
 AUC12 31.5 ± 3.4 31.2 ± 2.1 23.6 ± 2.1 8.07 0.0032 0.044 -0.96 (-6.7, 4.8) NS -8.9 (-15, -3.2) <0.001 -8.0 (-14, -8.0) 0.0032 
 
Androstenedione Tmax 3.46 ± 0.57 3.96 ± 0.51 2.83 ± 0.82 0.76 NS NS 0.50 (-1.6, 2.6) NS -0.63 (-2.8, 1.5) NS -1.1 (-3.3, -1.1) NS 
 
in men Cmax 2.68 ± 0.18 2.52 ± 0.18 2.14 ± 0.19 8.42 0.0019 0.027 -0.16 (-0.47, 0.15) NS -0.53 (-0.84, -0.22) <0.001 -0.37 (-0.69, -0.37) 0.014 
 
 AUC12 22.3 ± 1.2 23.0 ± 1.6 18.7 ± 1.8 8.66 0.0017 0.023 0.64 (-1.9, 3.2) NS -3.6 (-6.2, -1.0) 0.0031 -4.2 (-6.8, -4.2) <0.001 
 
Testosterone Tmax 3.32 ± 0.96 6.25 ± 0.83 3.64 ± 1.05 2.36 NS NS 2.6 (-0.60, 5.7) NS 0.05 (-3.1, 3.2) NS -2.5 (-5.6, -2.5) NS 
 
in women Cmax 0.88 ± 0.1 0.88 ± 0.1 0.87 ± 0.14 0.15 NS NS 0.01 (-0.26, 0.28) NS 0.06 (-0.21, 0.33) NS 0.05 (-0.22, 0.05) NS 
 
 AUC12 9.25 ± 1.1 9.59 ± 1.2 8.14 ± 0.98 0.77 NS NS 0.50 (-1.2, 2.2) NS -0.42 (-2.2, 1.3) NS -0.92 (-2.7, -0.92) NS 
 
Testosterone Tmax 4.21 ± 1.0 4.75 ± 0.66 3.50 ± 0.79 0.64 NS NS 0.54 (-2.1, 3.1) NS -0.71 (-3.3, 1.9) NS -1.3 (-3.9, -1.3) NS 
 
in men Cmax 6.23 ± 0.40 6.17 ± 0.4 5.69 ± 0.37 1.46 NS NS -0.06 (-0.87, 0.74) NS -0.54 (-1.3, 0.27) NS -0.47 (-1.3, -0.47) NS 
 
 AUC12 62.0 ± 4.3 62.0 ± 3.8 57.0 ± 3.6 1.59 NS NS 0.00 (-7.7, 7.7) NS -5.1 (-13, 2.6) NS -5.1 (-13, -5.1) NS 
 
Testosterone + Tmax 3.41 ± 0.52 5.13 ± 0.58 2.50 ± 0.78 4.14 0.033 NS 1.9 (-0.29, 4.1) NS -0.70 (-2.9, 1.5) NS -2.6 (-4.8, -2.6) 0.015 
 
androstenedione Cmax 4.45 ± 0.39 4.30 ± 0.22 3.40 ± 0.28 7.74 0.0038 0.053 -0.15 (-0.82, 0.53) NS -1.0 (-1.7, -0.37) <0.001 -0.90 (-1.6, -0.90) 0.0051 
 
in women AUC12 40.8 ± 3.5 40.8 ± 2.2 31.7 ± 2.4 6.83 0.0062 0.087 -0.46 (-7.2, 6.2) NS -9.4 (-16, -2.7) 0.0032 -8.9 (-16, -8.9) 0.0052 
 
Testosterone + Tmax 4.38 ± 0.96 4.13 ± 0.62 3.04 ± 0.69 0.84 NS NS -0.25 (-2.8, 2.3) NS -1.3 (-3.9, 1.2) NS -1.1 (-3.6, -1.1) NS 
 
androstenedione Cmax 8.50 ± 0.48 8.54 ± 0.48 7.62 ± 0.51 2.86 0.079 NS 0.05 (-0.97, 1.1) NS -0.87 (-1.9, 0.14) NS -0.92 (-1.9, -0.92) 0.086 
 
in men AUC12 84.4 ± 4.7 85.0 ± 4.7 75.7 ± 4.7 3.19 0.061 NS 0.64 (-9.0, 10) NS -8.7 (-18, 0.99) 0.089 -9.3 (-19, -9.3) 0.061 
Progestins      
 
        
 
Progesterone Tmax 5.73 ± 1.3 6.54 ± 0.98 4.73 ± 1.4 0.15 NS NS 0.45 (-4.0, 4.9) NS -0.60 (-5.1, 3.9) NS -1.1 (-5.5, -1.1) NS 
 
in women Cmax 3.38 ± 2.4 4.95 ± 3.2 1.94 ± 1.1 0.76 NS NS 2.2 (-5.0, 9.3) NS -1.6 (-8.8, 5.6) NS -3.8 (-11, -3.8) NS 
 
 AUC12 31.8 ± 24.4 41.6 ± 26.7 17.4 ± 11.7 0.57 NS NS 14 (-52, 81) NS -16 (-83, 51) NS -30 (-97, -30) NS 
 
Progesterone   Tmax 3.25 ± 0.40 3.42 ± 0.6 4.75 ± 0.94 1.53 NS NS 0.17 (-2.0, 2.4) NS 1.5 (-0.70, 3.7) NS 1.3 (-0.87, 1.3) NS 
 
in men Cmax 0.52 ± 0.06 0.50 ± 0.06 0.39 ± 0.06 13.7 <0.001 0.0019 -0.02 (-0.08, 0.04) NS -0.13 (-0.19, -0.06) <0.001 -0.11 (-0.17, -0.11) <0.001 
 
 AUC12 4.34 ± 0.64 4.47 ± 0.64 3.84 ± 0.68 13.9 <0.001 0.0018 0.13 (-0.16, 0.43) NS -0.50 (-0.79, -0.20) <0.001 -0.63 (-0.93, -0.63) <0.001 
 
17α-Hydroxy- Tmax 4.20 ± 0.58 4.27 ± 0.35 4.24 ± 0.79 0.02 NS NS 0.00 (-2.0, 2.0) NS 0.14 (-1.9, 2.2) NS 0.14 (-1.9, 0.14) NS 
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progesterone Cmax 4.01 ± 0.47 3.72 ± 0.46 2.91 ± 0.58 2.97 0.062 NS -0.19 (-1.3, 0.96) NS -1.1 (-2.3, 0.03) 0.059 -0.93 (-2.1, -0.93) NS 
 
 AUC12 31.2 ± 3.8 30.8 ± 4.0 24.5 ± 5.0 1.63 NS NS 0.48 (-9.9, 11) NS -6.7 (-17, 3.7) NS -7.2 (-18, -7.2) NS 
Values for amphetamine and steroids are mean ± SEM in 23, 24 and 23 subjects after administration of D-amphetamine, lisdexamfetamine and placebo, respectively. Values for the subjective effects are from 24 subjects (mean ± SEM). CI, 
Confidence Interval 95%; Tonset, time to reach 10% of Cmax (h); Cmax, peak plasma concentration (nM); Emax, maximal effect on the Visual Analog Scale (%max); NS, not significant (p value > 0.1); Tmax, time to reach Cmax (h); AUC12, area 
under the concentration–time curve to 12 h (ng×h/mL and nM×h and for amphetamine and steroids, respectively); DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; afor amphetamine F1,22; bSubjective effects: 
Tonset/max: F1,20, Emax and AUC12: F2,46; conly women F2,18 or only men F2,22. There were no significant differences in the steroid plasma concentrations between D-amphetamine and lisdexamfetamine.  
  329 
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Effects of D-amphetamine and lisdexamfetamine on plasma 330 
steroid and adrenocorticotropic hormone concentrations 331 
The effects of D-amphetamine, lisdexamfetamine, and placebo on plasma steroid 332 
hormone concentrations are shown in Fig. 3 and 4. Table 1 shows the corresponding Tmax, 333 
Cmax, and AUC values, with comparative statistics.  334 
Sex steroid levels were different between males and females when sex was added as 335 
additional factor to the ANOVAs (effects of sex: F1,20 = 5.34, p = 0.032; 184, p < 0.001; 3.21, 336 
p = 0.088;, and 61.7, p < 0.001, for androstenedione, testosterone, progesterone, and  337 
testosterone+androstenedione, respectively) but sex did not moderate the drug effects (no 338 
relevant sex × drug interactions [Supplementary Table S1]). Therefore, ANOVAs were 339 
conducted and results shown for each sex separately for androstenedione, testosterone, 340 
progesterone, and testosterone+androstenedione.  341 
Both active treatments significantly and similarly increased the plasma concentrations 342 
of the glucocorticoids cortisol, cortisone, corticosterone, 11-dehydrocorticosterone, and 11-343 
deoxycortisol compared with placebo (Fig. 3A-E, Table 1). Elevated glucocorticoid production 344 
was reflected by significant increases in the sums of active and inactive glucocorticoids (i.e., 345 
cortisol+cortisone, corticosterone+11-dehydrocorticosterone; Table 1) and all glucocorticoids 346 
measured (data not shown). The cortisol/cortisone and corticosterone/11-347 
dehydrocorticosterone ratios also increased (Table 1). The pharmacokinetic parameters, such 348 
as Cmax, Tmax, and AUC12, and the shape of the concentration-time curves for corticosteroids 349 
were practically identical following D-amphetamine and lisdexamfetamine administration (Fig. 350 
3, Table 1). The mineralocorticoids aldosterone (Fig. 3F) and 11-deoxycorticosteone (data not 351 
shown) and the progestogen 17α-hydroxyprogesterone (Fig. 4C) were unaltered by 352 
lisdexamfetamine and D-amphetamine compared with placebo. One exception was plasma 353 
progesterone concentrations in men, in which greater Cmax and AUC values were found 354 
compared with placebo (Table 1, Supplementary Fig. S1). Progesterone in women was not 355 
significantly altered, although a trend toward an increase was observed (Supplementary Fig. 356 
S1). The plasma concentrations of DHEA, DHEAS, and androstenedione (Fig. 4A, B, D, E) 357 
were significantly increased by the two active drugs compared with placebo. However, 358 
lisdexamfetamine and D-amphetamine had no effect on Cmax and AUC values for the sum of 359 
androstenedione+testosterone neither in women nor in men. Moreover, lisdexamfetamine and 360 
D-amphetamine had no effect on the concentrations of testosterone and the androgen 361 
degradation metabolite androsterone (Table 1). The plasma concentrations of 11-362 
deoxycorticosterone were above the LOD but below the LLOQ; therefore, the quantification of 363 
this steroid was not validly possible. 364 
 365 
 366 
Figure 3. Plasma concentrations of glucocorticoids and mineralocorticoids (mean and 367 
SEM) following administration of D-amphetamine, lisdexamfetamine, and placebo in 23, 368 
24, and 23 subjects, respectively. CYP, cytochrome P450; HSD, hydroxysteroid 369 
dehydrogenase. Lisdexamfetamine and D-amphetamine significantly increased the plasma 370 
concentrations of the glucocorticoids 11-deoxycortisol (A), 11-dehydrocorticosterone (B), 371 
cortisol (C), cortisone (E), and corticosterone (D) compared with placebo. The plasma 372 
concentration of aldosterone (F) was unaltered after D-amphetamine and lisdexamfetamine 373 
administration compared with placebo. 374 
 375 
Figure 4. Plasma concentrations of androgens and one progestogen (mean and SEM) 376 
following administration of D-amphetamine, lisdexamfetamine, and placebo in 23, 24, 377 
and 23 subjects, respectively. The data in men represent the mean and SEM in 12 subjects. 378 
The data in women represent the mean and SEM in 11, 12, and 11 subjects following 379 
administration of D-amphetamine, lisdexamfetamine, and placebo, respectively. The plasma 380 
concentrations of dehydroepiandrosterone (DHEA) (A), dehydroepiandrosterone sulfate 381 
(DHEAS) (B), and androstenedione in women (D) and men (E) were significantly elevated 382 
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following administration of D-amphetamine and lisdexamfetamine compared with placebo, 383 
whereas no effect on 17α-hydroxyprogesterone (C) was observed.  384 
 385 
 386 
Plasma concentrations of ACTH are shown in Fig. 5. A main effect of drug was found 387 
at the 3.5 h time point (F2,40 = 33.83, p < 0.001), and both active drugs resulted in higher 388 
plasma ACTH concentrations compared with placebo at 3.5 h (both p < 0.001). There were 389 
no relevant order × treatment interactions in the ANOVAs, indicating the absence of 390 
confounding by treatment order as expected based on the counter-balanced design 391 
(Supplementary Table S1).   392 
 393 
 394 
Figure 5. Plasma concentration of ACTH measured 1 h before and 3.5 h after drug 395 
administration (mean and SEM). Plasma ACTH concentrations increased 3.5 h after D-396 
amphetamine and lisdexamfetamine administration compared with placebo. ***p < 0.001, 397 
compared with placebo. 398 
 399 
 400 
Relationship between plasma amphetamine and steroid 401 
concentrations after D-amphetamine and lisdexamfetamine 402 
administration 403 
Selected drug exposure-steroid concentration response relationships are shown in 404 
Supplementary Fig. S2. Clockwise hysteresis was observed, indicating acute pharmacological 405 
tolerance. 406 
 407 
Peak endocrine effects following D-amphetamine and 408 
lisdexamfetamine administration compared with other 409 
prototypical substances 410 
The peak endocrine effects of D-amphetamine, lisdexamfetamine, methylphenidate, 411 
MDMA, and LSD are shown in Table 2. The drug effects are presented as within-subject 412 
changes from placebo (placebo-corrected responses). D-amphetamine, lisdexamfetamine, 413 
and methylphenidate produced comparable increases in cortisol. D-amphetamine increased 414 
cortisone and 11-dehydrocorticosterone to greater levels than methylphenidate. MDMA 415 
induced higher peak concentrations of cortisol, lower levels of cortisone, but still higher 416 
cortisol+cortisone levels than D-amphetamine. LSD produced much higher peak 417 
concentrations of cortisol and corticosterone than D-amphetamine, but in contrast to MDMA, 418 
the levels of cortisone and 11-dehydrocorticosterone resembled those that were observed 419 
after D-amphetamine administration. 420 
 421 
Table 2. Peak effects of D-amphetamine, lisdexamfetamine, methylphenidate, MDMA, 422 
and LSD on plasma glucocorticoids. 423 
 
D-Amphetamine 
40 mg (N=22) 
Lisdexamfetamine 
100 mg (N=23) 
Methylphenidate 
60 mg (N=16)a 
MDMA 
125 mg (N=16)a 
LSD 
200 µg (N=16)b F4,88 p value 
Cortisol 314.5 ± 25.7 298.5 ± 17.4 275.7 ± 48.1 513.1 ± 51.9** 690.1 ± 54.3*** 20.4 <0.001 
Cortisone 38.0 ± 3.3 39.0 ± 3.1 18.1 ± 3.4*** 16.4 ± 3.3*** 37.5 ± 4.1 10.5 <0.001 
Cortisol + cortisone 337.8 ± 27.9 323.5 ± 19.5 288.8 ± 49.1 520.3 ± 54.0* 721.4 ± 55.6*** 19.3 <0.001 
Corticosterone 19.5 ± 2.7 16.4 ± 2.0 8.9 ± 2.5 27.6 ± 2.4 34.9 ± 3.8** 12.4 <0.001 
11-Dehydrocorticosterone 6.5 ± 0.8 6.1 ± 0.6 1.9 ± 0.4*** 4.3 ± 0.4 6.0 ± 0.9 7.68 <0.001 
Corticosterone + 11-
dehydrocorticosterone 26.0 ± 3.4 22.0 ± 2.6 10.3 ± 2.9** 31.6 ± 2.5 40.5 ± 4.6* 10.4 <0.001 
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Values are mean ± SEM of the peak differences from placebo. *P<0.05, **P<0.01, ***P<0.001 Tukey post hoc test compared with D-amphetamine. MDMA, 
3,4-methylenedioxymethamphetamine or ecstasy; LSD, lysergic acid diethylamide. Data were adjusted from aSeibert et al. 2014 and bStrajhar et al. 2016. 
 424 
 425 
 426 
 427 
 428 
Discussion 429 
The main finding of the present study was that the novel ADHD treatment 430 
lisdexamfetamine produced similar HPA axis stimulation and plasma steroid concentration-431 
time curves as the classic immediate-release D-amphetamine. These findings did not support 432 
the hypothesis of the study, in which we expected to observe a smaller and more prolonged 433 
endocrine response to lisdexamfetamine compared with D-amphetamine. The reason for the 434 
identical endocrine responses of the two amphetamine formulations was the unexpected 435 
finding of similar peak amphetamine concentrations after lisdexamfetamine and D-436 
amphetamine administration. Lisdexamfetamine had a significantly longer onset and thus also 437 
Tmax but otherwise a very similar plasma amphetamine concentration-time curve shape 438 
compared with D-amphetamine. D-Amphetamine administration 1 h later would likely have 439 
produced a pharmacokinetic profile that was almost identical to lisdexamfetamine. The steroid 440 
concentration-time curves were shifted to the right (delayed in time), similar to the plasma 441 
amphetamine concentration-time curve after lisdexamfetamine administration compared with 442 
D-amphetamine, but this effect did not reach statistical significance for any of the steroid 443 
concentration Tmax values. 444 
Unexpectedly, the present study found similar Cmax values for amphetamine and all of 445 
the steroids at equivalent doses of lisdexamfetamine and D-amphetamine, which is in contrast 446 
to the limited preclinical [10] and clinical [7, 8] data that were used to generate the present 447 
study hypotheses. Specifically, a previous study in rats found a lower Cmax for amphetamine 448 
after lisdexamfetamine administration compared with D-amphetamine administration [10], in 449 
contrast to the present human data. An initial pharmacokinetic study in humans (referred to in 450 
[7]) reportedly found a longer Tmax and lower Cmax for plasma amphetamine after 451 
lisdexamfetamine administration compared with immediate-release D-amphetamine. 452 
However, these data have not been published. The present relatively large study clearly 453 
showed comparable Cmax values for amphetamine after administration of both 454 
lisdexamfetamine and D-amphetamine, with equal AUC values, thus demonstrating the 455 
equivalence of the drug doses and formulations used (Fig. 2, Table 1, see also [11]). 456 
Additionally, in the present study, the subjective and cardiovascular responses to 457 
lisdexamfetamine and D-amphetamine did not differ as also reported in detail elsewhere [11]. 458 
In contrast, another study in chronic stimulant users found that 100 mg lisdexamfetamine 459 
induced lower ratings of subjective “drug liking” than 40 mg D-amphetamine [7]. However, 460 
ratings of euphoria, amphetamine-like effects, and stimulant effects did not differ between the 461 
two treatments [7]. Altogether, the present findings indicate that the pharmacokinetics and 462 
pharmacodynamics of a high dose of the newly marketed medication lisdexamfetamine were 463 
practically identical to an equimolar dose of the classic immediate-release D-amphetamine 464 
that was administered 1 h later. The present data indicate that the conversion of the prodrug 465 
lisdexamfetamine to D-amphetamine only delays the onset of the increase in amphetamine 466 
concentrations in the body, without causing relevant alterations in the slope or maximal 467 
concentrations. Therefore, lisdexamfetamine unlikely has prolonged clinical effects (aside 468 
from the later onset) or a lower abuse potential compared with immediate-release D-469 
amphetamine when used orally (unless the delayed onset is considered to reduce immediate 470 
rewarding effects). A lower risk of oral misuse may be expected with a slow elevation of plasma 471 
D-amphetamine concentrations and its associated effects, but this was clearly not the case, at 472 
least not at the doses tested in the present study. In contrast, extended-release amphetamines 473 
may have a lower and delayed Cmax compared with lisdexamfetamine [44]. Parenteral misuse 474 
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of lisdexamfetamine produced effects that were comparable to oral use [45, 46], suggesting 475 
an intranasal and intravenous abuse-deterrent property of lisdexamfetamine compared with 476 
D-amphetamine. 477 
The effects of lisdexamfetamine on the HPA axis have not been previously studied. In 478 
the present study, the effects of lisdexamfetamine and D-amphetamine on HPA axis activation 479 
were similar. Both amphetamines increased the concentrations of the active glucocorticoids 480 
cortisol and corticosterone and their respective inactive metabolite and precursor cortisone 481 
and 11-dehydrocorticosterone, which has been similarly reported for lower doses of D-482 
amphetamine [16, 25, 26, 28-31, 47]. The mineralocorticoids aldosterone and 11-483 
deoxycorticosterone were unaltered by lisdexamfetamine or D-amphetamine, in contrast to 484 
increases that were found after MDMA administration [13]. Plasma concentrations of the 485 
adrenal androgen precursors DHEA, DHEAS, and androstenedione increased, whereas 486 
testosterone and its degradation product androsterone were unaltered by the two D-487 
amphetamine formulations. Plasma progesterone levels increased compared with placebo in 488 
men. In women, the absolute increase appeared to be larger but did not reach significance 489 
because of high interindividual variability (Supplementary Fig. S1).  490 
In the present study, we statistically compared the endocrine effects and especially 491 
cortisol of D-amphetamine with other psychoactive substances that were tested in previous 492 
separate studies in our laboratory in healthy subjects under similar conditions [13, 41]. In 493 
contrast to our hypothesis, D-amphetamine and lisdexamfetamine produced effects on plasma 494 
cortisol and corticosterone concentrations that were comparable to methylphenidate. Although 495 
the effects of methylphenidate on these active corticosteroids did not reach significance 496 
compared with placebo in our previous smaller study [13], the respective effects of D-497 
amphetamine that were significant compared with placebo in the present study were not 498 
significantly greater than those of methylphenidate. However, D-amphetamine produced 499 
greater cortisone and 11-dehydrocorticosterone levels than methylphenidate. Nevertheless, 500 
the present study indicates that the overall effects of D-amphetamine, lisdexamfetamine, and 501 
methylphenidate on plasma steroids at equivalent psychostimulant doses [37] are largely 502 
congruent. 503 
Norepinephrine, DA, and 5-HT have all been implicated in mediating HPA axis 504 
stimulation [41, 48]. However, the relative contribution of these monoamines to psychotropic-505 
induced HPA axis stimulation in humans is unclear [48]. D-amphetamine may release cortisol 506 
mainly via NE [38]. Specifically, D-amphetamine more potently interacts with the NE 507 
transporter compared with the DA and 5-HT transporters, and it has a very low potency at the 508 
5-HT transporter [35]. Additionally, the effects of D-amphetamine and methamphetamine on 509 
plasma corticosteroids were blocked by α-adrenergic receptor antagonists [49] but not DA 510 
receptor antagonists [50]. Purely or predominantly serotonergic substances strongly stimulate 511 
the HPA axis [32, 41, 43]. In the present study, we also statistically compared the effects of D-512 
amphetamine with similar historical data on MDMA and LSD that were obtained in the same 513 
laboratory using the same clinical and analytical methods [13, 41]. Compared with D-514 
amphetamine and methylphenidate (which stimulate NE and DA), MDMA and LSD (which 515 
mainly stimulate 5-HT) produced greater increases in plasma concentrations of the biologically 516 
active glucocorticoids cortisol and corticosterone. Additionally, the MDMA-induced elevation 517 
of plasma cortisol was shown to be mediated by the release of 5-HT but not DA [51, 52]. These 518 
findings support the view that 5-HT activation primarily or more strongly increases plasma 519 
cortisol compared with activation of the DA or NE systems [13, 41, 43]. 520 
We found other differential effects of the substances studied herein on HPA axis 521 
stimulation. Notably, compared with D-amphetamine, MDMA-induced increases in cortisol and 522 
corticosterone were paralleled by relatively smaller changes in the respective 11β-523 
hydroxysteroid dehydrogenase 2 (11β-HSD2)-formed metabolite and precursor cortisone and 524 
11-dehydrocorticosterone, indicating impairments in 11β-HSD2 activity that were caused by 525 
inhibition or saturation at elevated substrate concentrations by MDMA. In contrast, the LSD-526 
induced increases in cortisol and corticosterone were significantly higher compared with D-527 
amphetamine, whereas the inactive metabolites cortisone and 11-dehydrocorticosterone 528 
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induced comparable increases as those after D-amphetamine administration. Both the 5-HT 529 
releaser MDMA and 5-HT receptor agonist LSD [42] increased the sum of cortisol+cortisone 530 
more than D-amphetamine, indicating greater glucocorticoid production. This finding further 531 
supports the critical role of 5-HT in HPA axis stimulation by psychoactive substances and 532 
supports the use of cortisol as a marker of acute 5-HT activation [13, 41, 43].  533 
In the present study, the endocrine response to both D-amphetamine formulations 534 
showed moderate acute tolerance, reflected by clockwise hysteresis of the amphetamine vs. 535 
cortisol or corticosterone concentration plots and as reported previously for the subjective 536 
response to D-amphetamine [53]. Plasma corticosterone levels normalized more rapidly than 537 
D-amphetamine disappeared from plasma (Supplementary Fig. S2). The characteristics of 538 
these hysteresis curves were similar after lisdexamfetamine and D-amphetamine 539 
administration, thus pointing towards the similarity of these two formulations in humans, in 540 
contrast to previous animal data on the pharmacokinetic-pharmacodynamic relationship [10]. 541 
Even more pronounced acute tolerance to the cortisol and corticosterone responses was 542 
previously reported for the amphetamine derivative MDMA [13, 41] but not for the direct 543 
receptor agonist LSD [41]. The effects of lisdexamfetamine and D-amphetamine on plasma 544 
concentrations of cortisol and corticosterone lasted 10-12 h in the present study, whereas the 545 
effects of MDMA lasted only 4-6 h. These findings may reflect the somewhat longer half-live 546 
of D-amphetamine compared with MDMA (11 h vs. 8 h, respectively) [54, 55] and likely also 547 
more pronounced acute tolerance to the effects of MDMA compared with D-amphetamine. 548 
Activation of the HPA axis by amphetamines may be clinically relevant. This activation 549 
reflects a pharmacological stress response and has been shown to include increases in other 550 
endocrine markers of stress, including copeptin, oxytocin, epinephrine, and NE in the case of 551 
MDMA [13, 15, 40, 56, 57]. In recreational settings, MDMA increased plasma cortisol levels 552 
by up to 800% [58]. These marked endocrine responses that are induced by psychostimulants 553 
may affect mood, energy metabolism, sleep, and immune function [12, 59]. For example, D-554 
amphetamine, methylphenidate, and MDMA increased natural killer cells in plasma, reflecting 555 
activation of innate immune function [12, 60]. Increases in plasma epinephrine concentrations 556 
after methylphenidate and MDMA administration were associated with acute increases in 557 
circulating natural killer cells [12]. Increases in plasma cortisol following MDMA administration 558 
correlated with MDMA’s cardiovascular effects and subjective “drug liking” [61]. Steroids may 559 
contribute to the mood-enhancing effects of psychostimulants [61-64], enhance the rewarding 560 
and reinforcing effects of drugs [24], and increase the risk of misuse. Furthermore, the 561 
disruption of circadian rhythms, including steroid secretion, has been associated with 562 
impairments in immune function, metabolic disturbances, eating and mood disorders, and 563 
cancer progression [65]. Several studies suggest that the chronic misuse of amphetamines 564 
interferes with HPA axis function and its circadian rhythms [66-68]. The effects of different 565 
chronic stimulant medications on cortisol levels in patients are unclear [69]. Some studies 566 
reported elevated morning or bedtime cortisol levels during treatment with methylphenidate 567 
and atomoxetine [70], transient increases in cortisol levels during methylphenidate treatment 568 
with normalization over 6 months [71], or no effect of methylphenidate [72]. Comparable data 569 
on the effects of chronic lisdexamfetamine and D-amphetamine administration on cortisol 570 
levels are lacking. Tolerance to subjective and cardiostimulant effects has been observed with 571 
chronic lisdexamfetamine use [73-75]. However, whether and to what extent tolerance 572 
develops to the neuroendocrine effects of chronic administration of these D-amphetamine 573 
formulations and the time-course of such tolerance remain to be determined. 574 
The present study has limitations. We used only single and relatively high doses of 575 
lisdexamfetamine and D-amphetamine. The single dose of 100 mg lisdexamfetamine was 576 
above the maximal therapeutic dose for the treatment of ADHD of 70 mg. However, the single 577 
dose of 100 mg lisdexamfetamine mimics the misuse of lisdexamfetamine and produces 578 
plasma D-amphetamine concentrations that were comparable to those of repeated daily 579 
administration of 70 mg lisdexamfetamine when steady state is reached. Furthermore, plasma 580 
exposure to D-amphetamine would be higher in children compared to adults after the 581 
administration of the same dose of lisdexamfetamine [76]. Nevertheless, we cannot exclude 582 
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possible differences in the pharmacokinetics and endocrine effects of lisdexamfetamine and 583 
D-amphetamine at lower or higher doses than those used in the present study. Additionally, 584 
we studied only acute administration. Repeated lisdexamfetamine administration may result 585 
in tolerance to its endocrine effects, which has been reported for subjective effects with chronic 586 
use [73-75]. Furthermore, the statistical comparisons between the effects of D-amphetamine, 587 
methylphenidate, MDMA, and LSD relied on data from different studies within the same 588 
laboratory, and thus such comparisons were indirect and not within the same study and 589 
subjects. Thus, we cannot exclude that the differences are due to differences between studies 590 
rather than drugs. This part of the study was also limited by the use of only one dose for all of 591 
the substances. 592 
 593 
Conclusion 594 
Lisdexamfetamine and an immediate-release D-amphetamine formulation produced 595 
similar peak plasma concentrations of active D-amphetamine and HPA axis stimulation in 596 
healthy subjects, suggesting similar pharmacokinetic, endocrine, and likely oral abuse-related 597 
properties. Moderate acute pharmacological tolerance to the endocrine response to 598 
lisdexamfetamine and D-amphetamine was observed. Whether chronic tolerance develops to 599 
the endocrine response of amphetamines requires further study. Comparable HPA axis 600 
activation was induced by the noradrenergic/dopaminergic substances lisdexamfetamine, D-601 
amphetamine, and methylphenidate, whereas the serotonergic substances MDMA and LSD 602 
induced significantly greater HPA axis activation, supporting a predominant role for 5-HT in 603 
HPA axis stimulation by psychoactive substances.  604 
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